Lyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, ...

Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual ...

BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory ...

In this phase 2 study, researchers sought to determine whether cytoreductive treatment with rituximab followed by epcoritamab would deepen responses and lower risk of cytokine release syndrome.

Show More From Medical Department I, Technical University of Dresden, Dresden; Medical Department II, Klinikum Aschaffenburg, Aschaffenburg; Medical Department I, Krankenhaus Neuperlach, Munich; ...

Chemotherapy is the primary treatment for non-Hodgkin lymphoma, though people may also receive it with immunotherapy. Chemotherapy remains the first-line treatment for non-Hodgkin lymphoma (NHL), a ...

Methylation of p15 and p16 Genes in Acute Promyelocytic Leukemia: Potential Diagnostic and Prognostic Significance PURPOSE: Treatment of low-grade gastric mucosa-associated lymphoid tissue lymphoma by ...

Please provide your email address to receive an email when new articles are posted on . Most patients in the high-risk study population had some response to treatment. All high-grade treatment-related ...